IP Library Granted Patent US 9,339,481
Granted Patent B2
US 9,339,481 · App. 13/856,084 · Granted May 17, 2016

Phosphate-binding magnesium salts and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,339,481
App. No.
13/856,084
Granted
May 17, 2016
Kind
B2
Abstract

The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.

Claims (24)

1. A composition suitable for treating hyperphosphatemia comprising a therapeutically effective dose of at least one calcium salt and at least one phosphate-binding magnesium salt, wherein the at least one phosphate-binding magnesium salt comprises magnesium glycinate, and wherein the composition is formulated for oral administration and the composition comprises an enteric coating.

2. The composition of claim 1 , wherein the magnesium glycinate binds at least about 50 mg phosphate per gram.

3. The composition of claim 1 , wherein the therapeutically effective dose of at least one calcium salt comprises about 20 mg to 1200 mg of calcium.

4. The composition of claim 1 , wherein the at least one calcium salt is selected from the group consisting of calcium acetate, calcium aceturate, calcium adipate, calcium alaninate, calcium alginate, calcium aminobutyrate, calcium arginate, calcium ascorbate, calcium aspartate, calcium benzoate, calcium besylate, calcium betainate, calcium bromide, calcium buteprate, calcium butyrate, calcium caproate, calcium carbesilate, calcium carbonate, calcium carboxymethylcellulose, calcium camitinate, calcium chloride, calcium ciclotate, calcium citrate, calcium cypionate, calcium enanthate, calcium esylate, calcium ethandisulfonate, calcium formate, calcium fumarate, calcium glucarate, calcium gluceptate, calcium gluconate, calcium glucuronate, calcium glutamate, calcium glycinate, calcium hippurate, calcium hyclate, calcium hydroxide, calcium iodide, calcium isethionate, calcium lactate, calcium lactobionate, calcium levulinate, calcium lysinate, calcium malate, calcium maleate, calcium mesylate, calcium metilsulfate, calcium methylsulfate, calcium naphthoate, calcium napsylate, calcium nicotinate, calcium nitrate, calcium oleate, calcium orotate, calcium oxide, calcium oxoglurate, calcium pamoate, calcium pantothenate, calcium picolinate, calcium pivalate, calcium polygalacturonate, calcium propionate, calcium sorbate, calcium steaglate, calcium stearate, calcium stearyl-2-lactylate, calcium succinate, calcium sulfate, calcium sulfite, calcium tartrate, calcium tebutate, calcium tosylate, calcium triflutate, calcium xinafoate, and combination thereof.

5. The composition of claim 1 , wherein the mass ratio of the at least one calcium salt to the at least one phosphate-binding magnesium salt is between about 100:1 and about 1:100.

6. The composition of claim 1 , wherein the mass ratio of the at least one calcium salt to the at least one phosphate-binding magnesium salt is between about 5:4 and about 4:5.

7. The composition of claim 6 , wherein the mass ratio of the at least one calcium salt to the at least one phosphate-binding magnesium salt is about 1:1.

8. The composition of claim 1 , wherein the at least one calcium salt comprises calcium acetate.

9. The composition of claim 8 , wherein the therapeutically effective dose of calcium acetate is about 340 mg and the therapeutically effective dose of magnesium glycinate is about 300 mg.

10. The composition of claim 1 , wherein the composition is in a form of a tablet, a cachet, a hard gelatin capsule, a soft gelatin capsule, a lozenge, suspension, or a bead.

11. A composition suitable for treating hyperphosphatemia comprising a therapeutically effective dose of at least one phosphate-binding magnesium salt, wherein the at least one phosphate-binding magnesium salt binds at least about 50 mg phosphate per gram, wherein the composition is formulated for oral administration and the composition comprises an enteric coating.

12. The composition of claim 11 , wherein the at least one phosphate-binding magnesium salt binds at least about 100 mg phosphate per gram.

13. The composition of claim 11 , wherein the at least one phosphate-binding magnesium salt is not magnesium carbonate.

14. The composition of claim 11 , wherein the at least one phosphate-binding magnesium salt is selected from the group consisting of magnesium aminobutyrate, magnesium arginate, magnesium aspartate, magnesium betainate, magnesium camitinate, magnesium glycinate, magnesium hydroxide, magnesium lysinate, magnesium oxide, magnesium propionate, and combination thereof.

15. The composition of claim 11 , wherein the therapeutically effective dose of at least one phosphate-binding magnesium salt comprises about 20 mg to 1200 mg magnesium.

16. The composition of claim 11 , wherein the composition is in a form of a tablet, a cachet, a hard gelatin capsule, a soft gelatin capsule, a lozenge, suspension, or a bead.

17. A method of treating hyperphosphatemia comprising administering to a subject in need of treatment the composition of claim 1 .

18. A method of treating hyperphosphatemia comprising administering to a subject in need of treatment a calcium salt and a phosphate-binding magnesium salt, wherein the phosphate-binding magnesium salt comprises magnesium glycinate.

19. A method of treating hyperphosphatemia comprising administering to a subject in need of treatment a composition of claim 11 .

20. The composition of claim 11 , further comprising at least one calcium salt.

21. The composition of claim 20 , wherein the at least one calcium salt is selected from the group consisting of calcium acetate, calcium aceturate, calcium adipate, calcium alaninate, calcium alginate, calcium aminobutyrate, calcium arginate, calcium ascorbate, calcium aspartate, calcium benzoate, calcium besylate, calcium betainate, calcium bromide, calcium buteprate, calcium butyrate, calcium caproate, calcium carbesilate, calcium carbonate, calcium carboxymethylcellulose, calcium camitinate, calcium chloride, calcium ciclotate, calcium citrate, calcium cypionate, calcium enanthate, calcium esylate, calcium ethandisulfonate, calcium formate, calcium fumarate, calcium glucarate, calcium gluceptate, calcium gluconate, calcium glucuronate, calcium glutamate, calcium glycinate, calcium hippurate, calcium hyclate, calcium hydroxide, calcium iodide, calcium isethionate, calcium lactate, calcium lactobionate, calcium levulinate, calcium lysinate, calcium malate, calcium maleate, calcium mesylate, calcium metilsulfate, calcium methylsulfate, calcium naphthoate, calcium napsylate, calcium nicotinate, calcium nitrate, calcium oleate, calcium orotate, calcium oxide, calcium oxoglurate, calcium pamoate, calcium pantothenate, calcium picolinate, calcium pivalate, calcium polygalacturonate, calcium propionate, calcium sorbate, calcium steaglate, calcium stearate, calcium stearyl-2-lactylate, calcium succinate, calcium sulfate, calcium sulfite, calcium tartrate, calcium tebutate, calcium tosylate, calcium triflutate, calcium xinafoate, and combinations thereof.

22. The composition of claim 20 , wherein the at least one calcium salt comprises calcium acetate.

23. The method of claim 18 , wherein the calcium salt is selected from the group consisting of calcium acetate, calcium aceturate, calcium adipate, calcium alaninate, calcium alginate, calcium aminobutyrate, calcium arginate, calcium ascorbate, calcium aspartate, calcium benzoate, calcium besylate, calcium betainate, calcium bromide, calcium buteprate, calcium butyrate, calcium caproate, calcium carbesilate, calcium carbonate, calcium carboxymethylcellulose, calcium camitinate, calcium chloride, calcium ciclotate, calcium citrate, calcium cypionate, calcium enanthate, calcium esylate, calcium ethandisulfonate, calcium formate, calcium fumarate, calcium glucarate, calcium gluceptate, calcium gluconate, calcium glucuronate, calcium glutamate, calcium glycinate, calcium hippurate, calcium hyclate, calcium hydroxide, calcium iodide, calcium isethionate, calcium lactate, calcium lactobionate, calcium levulinate, calcium lysinate, calcium malate, calcium maleate, calcium mesylate, calcium metilsulfate, calcium methylsulfate, calcium naphthoate, calcium napsylate, calcium nicotinate, calcium nitrate, calcium oleate, calcium orotate, calcium oxide, calcium oxoglurate, calcium pamoate, calcium pantothenate, calcium picolinate, calcium pivalate, calcium polygalacturonate, calcium propionate, calcium sorbate, calcium steaglate, calcium stearate, calcium stearyl-2-lactylate, calcium succinate, calcium sulfate, calcium sulfite, calcium tartrate, calcium tebutate, calcium tosylate, calcium triflutate, calcium xinafoate, and combinations thereof.

24. The method of claim 18 , wherein the calcium salt comprises calcium acetate.

Assignments (6)
SECURITY INTEREST Recorded Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: CYPRESS PHRAMACEUTICALS, INC.
To: CURRAX PHARMACEUTICALS LLC
Reel/Frame 049329/0945 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2015
From: PERNIX THERAPEUTICS HOLDINGS, INC.
To: CYPRESS PHARMACEUTICALS, INC.
Reel/Frame 036387/0660 →
STOCK POWER/STOCK CERTIFICATES Recorded Jan 17, 2014
From: CYPRESS PHARMACEUTICALS, INC.
To: PERNIX THERAPEUTICS HOLDINGS, INC.
Reel/Frame 032076/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2013
From: LEWIS, ROBERT L.; DAY, CHARLES E.
To: CYPRESS PHARMACEUTICAL, INC.
Reel/Frame 031260/0869 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: LEWIS, ROBERT L.; DAY, CHARLES E.
To: CYPRESS PHARMACEUTICALS, INC.
Reel/Frame 030177/0017 →